Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 3/2017

01-09-2017 | Review Article

Is That Possible to Stop or Cease the NASH to Turn into HCC?

Author: Ahmet Uygun

Published in: Journal of Gastrointestinal Cancer | Issue 3/2017

Login to get access

Excerpt

We do not exactly know this because the etiopathogenesis of non-alcoholic steatohepatitis (NASH) is not completely known. But this progression can slow down by taking certain measures. …
Literature
1.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implication. Gastroenterology. 2012;142:711–25.CrossRef
2.
Mc Cullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:17–29.
3.
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease. A multicenter prospective study. Hepatology 2015; 24; 28363.
4.
Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open. 2014;20:4967–73.
5.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patient with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95.CrossRef
6.
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59.CrossRef
7.
Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.CrossRef
8.
Sorrentino P, D’Angelo S, Ferbo U, Micheli P, et al. Liver iron excess in patients with HCC developed on NASH. J Hepatol. 2009;50:351–7.CrossRef
9.
Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;13:1776–83.CrossRef
10.
Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi et al. Lipotoxicity in the liver. World J. Hepatol 2013; 5: 550–557.CrossRef
11.
Henao-Mejia J, Elinav E, Jin C, Hao L, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–85.CrossRef
12.
Oliveira CP, Stefano JT. Genetic polymorphisms and oxidative stress in NASH: a mini review. Clin res Hepatol Gastroenterol. 2015;39:35–40.CrossRef
13.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J med. 2003;348:1625–38.CrossRef
14.
Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742–54.CrossRef
15.
Karagozian R, Derdak Z, Baffy G. Obesity–associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRef
16.
Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.CrossRef
17.
Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with NASH who develop HCC. Clin Gastroenterol Hepatol. 2011;9:428–33.CrossRef
18.
Adami HO, Chow WO, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–7.CrossRef
19.
Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in NAFLD. Hepatology. 2011;53:448–57.CrossRef
20.
Hsiao PJ, Kuo KK, Shin SJ, Yang YH, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118–23.CrossRef
21.
Mc Glynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–43.CrossRef
22.
Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217–28.PubMedPubMedCentral
23.
Speliotes EK, Yerges-Armstrong LM, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:1324–38.CrossRef
24.
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to NAFLD. Nat Genet. 2008;40:1461–5.CrossRef
25.
Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109:325–34.CrossRef
26.
Shen JH, Li YL, Li D, et al. The rs738409 (IL48M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid res. 2014:487–95.
27.
Zhu L, Baker SS, Gill C, et al. Characterization of the gut microbiome in NASH patients: a connection between endogenonus aicohol and NASH. Hepatology. 2013;57:601–9.CrossRef
28.
Ren Z, Xu S, Jiang J, Zheng S. A novel diagnosis for early HCC based on intestinal microbiome. 21st Annual Meeting of the İnternational Liver Transplant Society, Chicago, 2015.
29.
Dapito DH, Mencin A, Gwak GY, et al. Promotion of HCC by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.CrossRef
30.
Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–54.CrossRef
31.
Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of HCC: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–91.CrossRef
32.
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of HCC in NAFLD: a multicenter prospective study. Hepatology. 2015;47:36–9.
33.
Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.CrossRef
34.
Leung C, Yeoh SW, Patrick D, et al. Characteristics of HCC in cirrhotic and non-cirrhotic NAFLD. World J Gastroenterol. 2015;21:1189–96.CrossRef
35.
Torres DM, Harrison SA. NASH and non-cirrhotic HCC: fertile soil. Semin Liver dis. 2012;32:30–8.CrossRef
36.
Schutte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with HCC in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117–25.CrossRef
37.
Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;604860
38.
Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of NASH: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRef
39.
Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with HCC in the United States. Hepatology. 2002;3:1349–54.CrossRef
40.
Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17:774–88.CrossRef
41.
Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinemia and insulin signalling in the pathogenesis and the clinical course of HCC. Liver Int. 2015;35:2203–17.CrossRef
42.
Zhao L. The gut microbiota and obesity: from correlation to causality. Nat rev Microbiol. 2013;11:639–47.CrossRef
43.
Dongiovanni P, Romeo S, Valenti L. HCC in NAFL: role of environmental and genetic factors. World J Gastroenterol. 2014;20:12945–55.CrossRef
44.
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.CrossRef
45.
Yun YH, Lim MK, Won YJ, et al. Dietary preference, physical activity and cancer risk in men: national health insurance corporation study. BMC Cancer. 2008;8:366.CrossRef
46.
47.
Fedirko V, Duarte-Salles T, Bamia C, et al. Prediagnostic circulating vitamin D levels and risk of HCC in European populations: a nested case-control study. Hepatology. 2014;60:1222–30.CrossRef
48.
Turati F, Trichopoulos D, Polesel J, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol. 2014;60:606–11.CrossRef
49.
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.CrossRef
50.
Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of HCC in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48:78–87.CrossRef
51.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRef
52.
Pei Y, Zhang T, Renault V, Zhang X. An overview of HCC study by omics-based methods. Acta Biochim Biophys sin. 2009;41:1–15.CrossRef
53.
Takaki Y, Saito Y, Takasugi A, et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from NASH. Cancer Sci. 2014;105:1254–60.CrossRef
54.
Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of NAFLD associted HCC. J Hepatol. 2014;61:75–81.CrossRef
Metadata
Title
Is That Possible to Stop or Cease the NASH to Turn into HCC?
Author
Ahmet Uygun
Publication date
01-09-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2017
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9961-6

Other articles of this Issue 3/2017

Journal of Gastrointestinal Cancer 3/2017 Go to the issue

Review Article

New Paradigm: Adaptive Approach

Review Article

Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma

Review Article

Barcelona Clinic Liver Cancer (BCLC) Staging: Does It Cover All Our Expectation

Review Article

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)

Abstract

Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience

Abstract

The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits